The Immune Response Corporation (OTCBB: IMNR) – Tuesday’s shares went up 0.51% to $0.0199. 4,372,130 shares were traded. The Immune Response Corporation announced on October 30th that Dr. Joseph O’Neill, President and CEO, will present an overview of the Company’s immune-based therapies, currently in Phase II clinical trials, at the Rodman & Renshaw Eighth Annual Healthcare Conference in New York City. The Company’s presentation to the investment community will take place on Tuesday, November 7, 2006, at 3:55 p.m. (EST). Dr. O’Neill will discuss a key strategic agreement, signed October 10, 2006, with Accelsiors CRO & Consultancy Services, a clinical research organization (CRO) with extensive experience in conducting multiple sclerosis (MS) trials, to oversee a 200-patient Phase IIb trial of NeuroVax(TM), an investigational T-cell receptor (TCR) peptide vaccine for the treatment of multiple sclerosis (MS). He will review in detail the Company’s drug development pipeline, and status of the Phase II clinical trials in progress for NeuroVax, and for IR103, for the treatment of human immunodeficiency virus (HIV). IR103 is based on the Company’s patented whole-inactivated virus technology, co-invented by Dr. Jonas Salk.
The Immune Response Corporation is an immuno-pharmaceutical company focused on developing products to treat autoimmune and infectious diseases. The Company’s lead immune-based therapeutic product candidates are NeuroVax for the treatment of MS and IR103 for the treatment of HIV infection. Both of these therapies are in Phase II clinical development and are designed to stimulate pathogen-specific immune responses aimed at slowing or halting the rate of disease progression.
Rotoblock Corporation (OTCBB: ROTB)
Rotoblock (OTCBB: ROTB) – Tuesday’s shares stayed even at $0.10. The volume was 33,200.� Rotoblock announced on October 25th it won an extension to own and market the Oscillating Piston Engine; a unique and highly advanced internal engine that will give automobiles, airplanes, boats and many other mobile and stationery applications much more power. Rotoblock has spent the last several months negotiating terms to the patent rights and has now signed a 37 month extension agreement which gives Rotoblock extended exclusive rights on the powerful technology. According to Rotoblock President, Matthias Heinze, “We are thrilled for what it means to the health of our company. Now that we are no longer on hold waiting for this extention, we will immediately exploit new markets such as China and India where we know our technology is in high demand. Every indication shows that the Oscillating Piston Engine should surpass performance of current combustion engines on several levels. It is expected to become very popular in the automotive, aviation and marine markets.”
Rotoblock (OTCBB: ROTB) is focused on the development of advanced propulsion system technologies including the continued development and improvement of the Oscillating Piston Engine to the state where its mechanical, ecological and economic viability leads to the profitable licensing of the manufacturer’s rights to a proprietary patented design or a partnership for its manufacture. The Company was incorporated in Nevada, and is headquartered in Santa Rosa, California. The Company has full rights to the patents of the original Oscillating Piston Engine and believes the Rotoblock Oscillating Piston Engine has particular and useful applications in developing countries such as China and India and will be including these areas in the marketing and commercialization phase of this engine.
Northamerican Energy Group Corp. (OTC: NNYG)
Northamerican Energy Group Corp. (OTC: NNYG) -� Tuesday’s shares stayed even at $0.018. 78,000 was the volume. Northamerican Energy Group Corporation announced on October 24th that it executed an exclusive option with Penergy, of Midland, Texas, to purchase the leases on 1,920 acres encompassing the South Leonard (Queen/Penrose) and Rhodes (Yates/Seven Rivers) Fields in Lea County, New Mexico. These leases have 30 existing wells originally drilled by Tenneco into shallow (under 3000′) reservoirs, with just one of the existing wells currently operating out of the Yates formation; however many of the remaining 29 wells that were temporarily shut in can easily be reworked, at nominal cost, to bring them back on line with anticipated production of 5-10 Blpd of oil, and 50-100 Mcfd of natural gas. The 3-D Seismic, and geological surveys, of both these leases, and in adjacent leases east, and northeast of these leases show good promise and potential in the Devonian (9200′) and EllenBurger (11,700′) zones, as verified by initial natural gas potential of 1555 Mcfpd, 1668 Mcfpd and 4249 Mcfpd in the offsetting wells, as shown in the production reports of the east coast petroleum producer that drilled them.
Northamerican Energy Group Corp. specializes in acquiring Oil and Gas leases with proven reserves that have the potential for increased oil and natural gas production utilizing the new well production stimulation systems currently available. Northamerican’s main objective is to locate and acquire Oil and Gas Leases with upside potential for enhanced recovery and to accomplish this by employing: new and vastly improved chemical treatments for treating existing wells, acquisitions where the full potential of the lease has never been properly exploited, well workovers that utilize new equipment and technology, developmental drilling programs to drill new wells into existing proven reserves, and chemical fracture stimulation systems to improve production.
ALR Technologies, Inc. (OTCBB: ALRT)
ALR Technologies, Inc. (OTCBB: ALRT) – Tuesday’s shares closed down 16.67% to $0.10. 1,000 shares were traded.� ALR Technologies announced on October 30th that Apple Patch Community, an assisted living organization that is utilizing the ALRT500 system, received a special invitation to present at the prestigious 2006 Institute For Behavioral Health Informatics conference about their innovative, leading edge method for assisted living care for those with mental retardation. Apple Patch executive director, Chris Stevenson, reports that their use of the ALRT500 compliance reminder and monitoring system has generated attention at the national level and that the Apple Patch Community care approach and the ALRT500 monitoring system will be presented in detail at this national meeting on November 9th and 10th in Arlington, VA. “Several officials and companies have heard about the ALRT system since we began use a few months ago and called me about it,” reports Stevenson. “The ALRT compliance system has provided our caregivers with the assistance needed to remember to complete or administer the many activities and medications that are essential for quality care. The ability to remind and to monitor at such an affordable price is remarkable. We expected the cost to be substantially higher. Our monitoring has allowed for education changes and timing changes to help improve behavior. Not only are we providing more accurate and timely care but it also makes us more cost efficient.”
ALR Technologies, Inc. is a pioneer in the emerging market for home health management and disease management industry. ALRT has developed technology-based, “clinically proven” medication reminder products and compliance monitoring and health intervention systems servicing the health care industry. ALRT?s products have been developed to address the growing problem of patient adherence to medical disease management treatments and activities that contribute to more than $140 billion dollars annually in excess healthcare costs. Healthcare costs in the US account for 15% of the gross domestic product and is expected to reach 25% by 2020. ALRT?s flagship product, the ALRT500 Health Management system, provides continued ongoing assistance to the patient and continued oversight after the patient has been released from the hospital, medical clinic, or the case manager has left their home.
GeneThera Inc. (OTCBB: GTHA)
GeneThera Inc. (OTCBB: GTHA) – Tuesday’s shares decreased 8.33% to $0.055. The volume was 148,600. GeneThera announced on October 26th that the Company purchased three Tecan Freedom EVO(r) 200 systems for installation in the Company’s Italian, Mexican and Colorado laboratory facilities. Once installed, GeneThera will have the ability to begin the validation process for its Mad Cow Disease Live Animal Assay as well as other veterinary diseases as previously announced. “The Tecan product is a superior state of the art system that will allow GeneThera to streamline our live animal blood testing and allow us to automatically run our tests with 100% accuracy,” said Dr. Tony Milici, CEO. “By using the Freedom EVO(r) 200 system in conjunction with the Freedom EVOware(r) software, the system will automate our application quickly and easily. The Freedom EVO(r) system will allow each lab to come on-line much sooner without the delay of training personnel on new products and procedures.”
GeneThera, Inc., a development stage company, develops molecular assays for the detection of food contaminating pathogens, veterinary diseases, and genetically modified organisms primarily in the United States. In addition, it is in process of developing therapeutic vaccines for the detection of chronic wasting disease, a disease affecting elk and deer in North America; and mad cow disease. GeneThera has an agreement with Istituto Zooprofilattico Sperimentale della Lombardia e dell’Emilia Romagna to collaborate on scientific research related to the diagnosis of animal transmittable diseases, such as Mad Cow Disease and Scrapie. The company, formerly known as Hand Brand Distribution, Inc., was founded by Antonio Milici. GeneThera was incorporated in 1995 and is based in Wheat Ridge, Colorado.
Dragon International Group Corporation (OTCBB: DRGG)
Dragon International Group Corporation (OTCBB: DRGG) – Tuesday’s shares went up 2.31% to $0.133. 819,208 was the volume.� Dragon International Group Corp. announced on October 31st that its wholly owned subsidiary, Shanghai JinKui Packaging Material Company, Limited (”JinKui”), received a purchase order from Wutai Pharmaceutical Group (”Wutai”). Under the terms of the purchase order, JinKui will supply 8-10 metric tons of cold aluminum packaging film per month over the next two years. Mr. David Wu, CEO and Chairman of Dragon International Group Corp., stated, “This purchase order is proof of our commitment to expand into the pharmaceutical packaging market. This marks another significant development since our acquisition of JinKui on June 300, 2006. China’s pharmaceutical packaging industry has witnessed strong, recurring growth in the past decade. Annual sales of pharmaceutical packaging have grown approximately 20% annually since 2004. We believe this market represents another tremendous growth opportunity for our shareholders for years to come.”
Dragon International Group Corporation is one of China’s leading paper manufacturers and a distributor of a wide range of specialty paper products and packaging material. The company’s products are utilized for high end packaging in the cigarette, alcohol, gift, cosmetics, tea, and pharmaceutical industries. Dragon International has served as an agent for International Paper Company and Asia Pulp and Paper since 1998. Dragon International’s newly developed products have higher quality features than products currently available in the marketplace of China. These packaging products have the potential to immediately dominate a market currently dominated by low end packaging. Packaging products for both the consumer market of China and for exports is a focus of this company’s rapid expansion.
We Invite you to Visit the All New StockGuru Blog!
Here you will find updates on all our covered companies, including Profiled Companies and StockGuru Picks.
Click HERE to visit the Blog, or go to:
http://stockguru.com/blog/
StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (214) 458-4258. Web: StockGuru.com. Email: Publisher@stockguru.com. IMNR Disclosure: Pentony Enterprises LLC was compensated $50,000 from ROI Group Associates Inc. for profile coverage. ROTB Disclosure: Pentony Enterprises LLC was compensated 250,000 free trading shares from a non-controlling third party for profile coverage. It is the policy of Pentony Enterprises LLC to sell all shares of this and any company featured. Anyone considering any company we feature in consideration for free trading shares should consider this. NNYG Disclosure: Pentony Enterprises LLC was compensated 2,700,000 free trading shares from a non-controlling third party for profile coverage. It is the policy of Pentony Enterprises LLC to sell all shares of this and any company featured. Anyone considering any company we feature in consideration for free trading shares should consider this. ALRT Disclosure: Pentony Enterprises LLC was compensated $15,000 from a non-controlling third party for profile coverage. GTHA Disclosure: Pentony Enterprises LLC was compensated 500,000 free trading shares from a non-controlling third party for profile coverage. It is the policy of Pentony Enterprises LLC to sell all shares of this and any company featured. Anyone considering any company we feature in consideration for free trading shares should consider this. We currently hold 233,000 shares. DRGG Disclosure: Pentony Enterprises LLC was compensated $22,500 from non-controlling third party ROI Group Associates for profile coverage. Pentony Enterprises LLC is not a registered investment advisers or broker/dealers. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this website is suitable or advisable for any person or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.